TMSP(SH:600671) Zheng Quan Zhi Xing·2025-08-27 09:59Core Viewpoint - Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd. reported significant growth in revenue for the first half of 2025, with a 73.97% increase compared to the same period last year, despite a decrease in total assets by 8.33% [1] Financial Summary - Total assets at the end of the reporting period were CNY 404.71 million, down from CNY 441.46 million at the end of the previous year, representing an 8.33% decrease [1] - Operating revenue for the reporting period reached CNY 103.60 million, compared to CNY 59.55 million in the same period last year, marking a 73.97% increase [1] - The total profit for the period was CNY 7.12 million, a significant recovery from a loss of CNY 21.38 million in the previous year [1] - Net profit attributable to shareholders of the listed company was CNY 5.90 million, compared to a loss of CNY 22.06 million in the same period last year [1] - The net cash flow from operating activities improved to -CNY 10.87 million, an improvement from -CNY 28.13 million in the previous year, indicating a 61.35% increase in cash flow [1] Shareholder Information - The total number of shareholders at the end of the reporting period was 8,381 [1] - The largest shareholder, Qingdao Huilong Huaze Investment Co., Ltd., holds 29.99% of the shares, amounting to 36,519,460 shares [2] - Other significant shareholders include Qingdao Yuanjia Medical Technology Co., Ltd. with 13.27% and Zhejiang Qingfeng Original Culture Co., Ltd. with 4.26% [2]